Association of dehydroepiandrosterone sulfate and testosterone deficiency with bone turnover in men with inflammatory bowel disease

被引:32
作者
Szathmári, M [1 ]
Vásárhelyi, B [1 ]
Treszl, A [1 ]
Tulassay, T [1 ]
Tulassay, Z [1 ]
机构
[1] Semmelweis Univ, Dept Med 1, H-1083 Budapest, Hungary
基金
匈牙利科学研究基金会;
关键词
bone mineral density; bone turnover; dehydroepiandrosterone sulfate; inflammatory bowel disease; testosterone;
D O I
10.1007/s003840100334
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: We investigated the coexistence of dehydroepiandrosterone sulfate (DHEAS) and testosterone deficiency in men with inflammatory bowel disease (IBD) and their relationship with bone homeostasis. Patient and methods: In 45 men with IBD (25 with ulcerative colitis, 20 with Crohn's disease) the testosterone and DHEAS levels were examined in relationship to bone mineral density, osteocalcin levels, and urinary deoxypyridinoline excretions. Results: We detected osteoporosis in 10 and osteopenia in 22 patients at the lumbar spine and/or femoral neck. Lower testosterone levels were measured in 20. Lower DHEAS levels were present in 23 patients; these had higher deoxypyridinoline excretion and lower lumbar spine and femoral neck BMD T scores than patients with normal DHEAS. DHEAS and BMD were correlated at the lumbar spine and the femoral neck. Associations remained significant after adjustment for age, weight, steroid use, and inflammatory activity. No independent effect of testosterone deficiency was detected on bone parameters. Conclusion: DHEAS deficiency may contribute to the bone loss of men with IBD. This putative action of DHEAS on bone turnover is contrary to the common effect of testosterone deficiency and steroid therapy.
引用
收藏
页码:63 / 66
页数:4
相关论文
共 13 条
[1]   METABOLIC BONE ASSESSMENT IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
ABITBOL, V ;
ROUX, C ;
CHAUSSADE, S ;
GUILLEMANT, S ;
KOLTA, S ;
DOUGADOS, M ;
COUTURIER, D ;
AMOR, B .
GASTROENTEROLOGY, 1995, 108 (02) :417-422
[2]   Reduced bone density in patients with inflammatory bowel disease [J].
Bjarnason, I ;
Macpherson, A ;
Mackintosh, C ;
BuxtonThomas, M ;
Forgacs, I ;
Moniz, C .
GUT, 1997, 40 (02) :228-233
[3]   HORMONE REPLACEMENT THERAPY PREVENTS BONE LOSS IN PATIENTS WITH INFLAMMATORY BOWEL-DISEASE [J].
CLEMENTS, D ;
COMPSTON, JE ;
EVANS, WD ;
RHODES, J .
GUT, 1993, 34 (11) :1543-1546
[4]  
de la Torre B, 1998, CLIN EXP RHEUMATOL, V16, P579
[5]  
De Vos M, 1998, ALIMENT PHARM THERAP, V12, P397
[6]   PHYSIOLOGICAL IMPORTANCE OF DEHYDROEPIANDROSTERONE [J].
EBELING, P ;
KOIVISTO, VA .
LANCET, 1994, 343 (8911) :1479-1481
[7]   Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study [J].
Garnero, P ;
Sornay-Rendu, E ;
Claustrat, B ;
Delmas, PD .
JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (08) :1526-1536
[8]   Bone mineral density is reduced in patients with Crohn's disease but not in patients with ulcerative colitis: A population based study [J].
Jahnsen, J ;
Falch, JA ;
Aadland, E ;
Mowinckel, P .
GUT, 1997, 40 (03) :313-319
[9]   AROMATASE DEFICIENCY IN MALE AND FEMALE SIBLINGS CAUSED BY A NOVEL MUTATION AND THE PHYSIOLOGICAL-ROLE OF ESTROGENS [J].
MORISHIMA, A ;
GRUMBACH, MM ;
SIMPSON, ER ;
FISHER, C ;
QIN, K .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (12) :3689-3698
[10]  
Robinson RJ, 1998, ALIMENT PHARM THERAP, V12, P21